Jonathan Lifshitz1,2,3,4, Rachel K Rowe1,2,3, Daniel R Griffiths1,2, Megan N Evilsizor1,2, Theresa C Thomas1,2,3,4, P David Adelson1,2,4, Tracy K McIntosh5. 1. a Translational Neurotrauma Research Program , BARROW Neurological Institute at Phoenix Children's Hospital , Phoenix , AZ , USA. 2. b Department of Child Health , University of Arizona, College of Medicine - Phoenix , Phoenix , AZ , USA. 3. c Phoenix VA Healthcare System , Phoenix , AZ , USA. 4. d Neuroscience Graduate Program , Arizona State University , Tempe , AZ , USA. 5. e Media NeuroConsultants, Inc ., Media , PA , USA.
Abstract
BACKGROUND: After 30 years of characterisation and implementation, fluid percussion injury (FPI) is firmly recognised as one of the best-characterised reproducible and clinically relevant models of TBI, encompassing concussion through diffuse axonal injury (DAI). Depending on the specific injury parameters (e.g. injury site, mechanical force), FPI can model diffuse TBI with or without a focal component and may be designated as mild-to-severe according to the chosen mechanical forces and resulting acute neurological responses. Among FPI models, midline FPI may best represent clinical diffuse TBI, because of the acute behavioural deficits, the transition to late-onset behavioural morbidities and the absence of gross histopathology. REVIEW: The goal here was to review acute and chronic physiological and behavioural deficits and morbidities associated with diffuse TBI induced by midline FPI. In the absence of neurodegenerative sequelae associated with focal injury, there is a need for biomarkers in the diagnostic, prognostic, predictive and therapeutic approaches to evaluate outcomes from TBI. CONCLUSIONS: The current literature suggests that midline FPI offers a clinically-relevant, validated model of diffuse TBI to investigators wishing to evaluate novel therapeutic strategies in the treatment of TBI and the utility of biomarkers in the delivery of healthcare to patients with brain injury.
BACKGROUND: After 30 years of characterisation and implementation, fluid percussion injury (FPI) is firmly recognised as one of the best-characterised reproducible and clinically relevant models of TBI, encompassing concussion through diffuse axonal injury (DAI). Depending on the specific injury parameters (e.g. injury site, mechanical force), FPI can model diffuse TBI with or without a focal component and may be designated as mild-to-severe according to the chosen mechanical forces and resulting acute neurological responses. Among FPI models, midline FPI may best represent clinical diffuse TBI, because of the acute behavioural deficits, the transition to late-onset behavioural morbidities and the absence of gross histopathology. REVIEW: The goal here was to review acute and chronic physiological and behavioural deficits and morbidities associated with diffuse TBI induced by midline FPI. In the absence of neurodegenerative sequelae associated with focal injury, there is a need for biomarkers in the diagnostic, prognostic, predictive and therapeutic approaches to evaluate outcomes from TBI. CONCLUSIONS: The current literature suggests that midline FPI offers a clinically-relevant, validated model of diffuse TBI to investigators wishing to evaluate novel therapeutic strategies in the treatment of TBI and the utility of biomarkers in the delivery of healthcare to patients with brain injury.
Authors: Jordan L Harrison; Rachel K Rowe; Timothy W Ellis; Nicole S Yee; Bruce F O'Hara; P David Adelson; Jonathan Lifshitz Journal: Brain Behav Immun Date: 2015-01-10 Impact factor: 7.217
Authors: D H Smith; X H Chen; J E Pierce; J A Wolf; J Q Trojanowski; D I Graham; T K McIntosh Journal: J Neurotrauma Date: 1997-10 Impact factor: 5.269
Authors: Rachel K Rowe; Jordan L Harrison; Helena W Morrison; Vignesh Subbian; Sean M Murphy; Jonathan Lifshitz Journal: J Neurotrauma Date: 2018-12-18 Impact factor: 5.269
Authors: Theresa Currier Thomas; Sarah B Ogle; Benjamin M Rumney; Hazel G May; P David Adelson; Jonathan Lifshitz Journal: Behav Brain Res Date: 2016-12-29 Impact factor: 3.332
Authors: Patricia B de la Tremblaye; Darik A O'Neil; Megan J LaPorte; Jeffrey P Cheng; Joshua A Beitchman; Theresa Currier Thomas; Corina O Bondi; Anthony E Kline Journal: Neurosci Biobehav Rev Date: 2017-05-30 Impact factor: 8.989
Authors: Vimala N Bharadwaj; Rachel K Rowe; Jordan Harrison; Chen Wu; Trent R Anderson; Jonathan Lifshitz; P David Adelson; Vikram D Kodibagkar; Sarah E Stabenfeldt Journal: Nanomedicine Date: 2018-06-19 Impact factor: 5.307
Authors: Kristina G Witcher; Julia E Dziabis; Chelsea E Bray; Alan J Gordillo; Julia E Kumar; Daniel S Eiferman; Jonathan P Godbout; Olga N Kokiko-Cochran Journal: Brain Res Date: 2020-06-24 Impact factor: 3.252
Authors: Joshua A Beitchman; Jonathan Lifshitz; Neil G Harris; Theresa Currier Thomas; Audrey D Lafrenaye; Anders Hånell; C Edward Dixon; John T Povlishock; Rachel K Rowe Journal: Neurotrauma Rep Date: 2021-02-08